Annual vaccinations reduced the number of hospitalisations in children by 50%, not only...
IDWeek 2019: Seasonal influenza vaccines prove their worth, but better vaccines are still needed
Annual vaccinations reduced the number of hospitalisations in children by 50%, not only in patients with pre-existing conditions but also in healthy children (40% of the cases).
Bavarian Nordic begins equine encephalitis virus vaccine trial
Bavarian Nordic has started a Phase I clinical trial to assess its vaccine candidate MVA-BN WEV for prophylaxis against equine encephalitis virus.
IDWeek 2019: Long-acting antiretroviral therapy shows promise for HIV patients with low adherence
HIV infections can be well controlled with antiretroviral therapy to a degree where the viral load is not detectable anymore.
IDWeek 2019: Delegates hear of viral challenge studies in clinical development of RSV therapeutics and vaccines
There are currently no products available for the treatment or prevention of RSV infections in populations outside of infants.
AstraZeneca’s Breztri Aerosphere is a late-stage blockbuster
GlobalData anticipates rapid approval for AstraZeneca triple-combination therapy inhaler Breztri Aerosphere in the EU and US.
Wistar secures funds for clinical studies on opioid use in HIV patients
The Wistar Institute in the US has received more than $12m in funding from the National Institute on Drug Abuse (NIDA) to support a clinical research consortium focused on opioid use in HIV patients.
Takeda’s maribavir shows promise in Phase II CMV infection study
Takeda Pharmaceutical has reported positive data from the Phase II clinical trial of its antiviral drug candidate maribavir (TAK-620) in cytomegalovirus (CMV) infection following hematopoietic cell or solid organ transplant.
Pfizer’s Phase II results strengthen likely regulatory approval for 20vPnC
Pfizer announced positive results for a Phase II study following administration of three doses in a four-dose series to assess the safety and immunogenicity of 20vPnC.